Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ZimVie Inc (ZIMV)
Analysts fell to the sidelines weighing in on SAGE Therapeutics (SAGE – Research Report) and ZimVie Inc (ZIMV – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SAGE Therapeutics (SAGE)
Wedbush analyst Laura Chico maintained a Hold rating on SAGE Therapeutics today and set a price target of $8.50. The company’s shares closed last Wednesday at $8.68.
According to TipRanks.com, Chico is a 4-star analyst with an average return of
SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.68.
See today’s best-performing stocks on TipRanks >>
ZimVie Inc (ZIMV)
In a report released today, David Saxon from Needham maintained a Hold rating on ZimVie Inc. The company’s shares closed last Wednesday at $18.88.
According to TipRanks.com, Saxon is a 1-star analyst with an average return of
ZimVie Inc has an analyst consensus of Hold, with a price target consensus of $16.00, a -14.8% downside from current levels. In a report issued on July 22, Barclays also upgraded the stock to Hold with a $19.00 price target.
Read More on SAGE:
Disclaimer & DisclosureReport an Issue
- Sage Therapeutics reports Q2 EPS (79c), consensus (94c)
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
